BNF:

8.1.5

Status:

Do Not Prescribe (DNP)

Decision Date:

May 2011

Comments

DO NOT PRESCRIBE (DNP)6: NICE TA222: Ovarian cancer relapsed - not recommended with pegylated liposomal doxorubicin for relapsed platinum sensitive ovarian cancer.

DO NOT PRESCRIBE (DNP)6: NICE TA 389: Trabectedin with pegylated liposomal doxorubicin hydrochloride is not recommended for treating the first recurrence of platinum‑sensitive ovarian cancer. TA 389 replaces TA222. (Decision date - May 2016).

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again